カテゴリー： Market Research Future, 世界, 医療/バイオ

ダーカム病の世界市場（〜2030）

◆英語タイトル：Global Dercum’s Disease Market Research Report Forecast till 2030
	◆商品コード：MRF23DCB010 ◆発行会社（リサーチ会社）：Market Research Future ◆発行日：2023年11月 ◆ページ数：115 ◆レポート形式：英語 / PDF ◆納品方法：Eメール ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（印刷不可、Online Access）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Enterprisewide Price（印刷可）	USD7,250 ⇒換算￥1,102,000	見積依頼/購入/質問フォーム

★Market Research Futureに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

ダーカム病の市場調査レポート：2030年までの予測
市場概要
ダーカム病市場は予測期間中にCAGR 6.76%を記録すると予測されます。興味深い疾患の優勢が高まっており、研究および進歩の運動が拡大していることが市場発展の原動力となっています。
コロナウイルスの継続的な大流行と並んで、例えば色脂肪症や脂肪腫のような珍しい疾患は、世界的に大きなウェイトを占めています。2021年2月に開催されたNCBIの調査によると、毎年およそ2500人の遊離結合（脂肪）組織疾患が見られ、ほとんどの患者が脂肪水腫、6人がFML-Type DD、10人が血管脂肪腫-Type Dercum病でした。さらに、同様のレビューでは、Dercum病の優位性は人口の0.64％であり、アメリカでの脂肪水腫の一般性は女性の11％と考えられていますが、その範囲は5〜39％であることが推奨されています。ダーカム病の患者の大部分は女性です。
その上、ダーカム病は、脂性組織（脂肪腫）の様々な、苦痛を伴う発展によって描写されます。このように、珍しい病気を経験する患者の数量は普遍的に拡大しています。また、コロナウイルスの増加も同様に、ダーカム病の市場開発に根本的な影響を与えます。このような疾患の症例数の増加は、ダーカム病に対する関心を世界的に拡大すると予想されます。

市場区分
ダーカム病の市場区分は、治療法に基づき、手術、薬物療法、脂肪吸引、電気療法、鍼治療、その他を含みます。
ダーカム病市場は、病院＆クリニック、外来手術センター、その他を含むエンドユーザーに基づいて細分化されます。流通チャネルに基づくと、市場は病院薬局、小売薬局、その他に分けられます。

地域別洞察
北米のダーカム病市場は2022年に最大の市場シェアを占めました。これは、一般的でない疾患治療薬やガジェットの改善、および同地域での薬物療法の承認に向けた理想的な政府の行為のためです。
また、ドイツは最大の市場シェアを占め、フランスはヨーロッパで最も急速に発展している市場です。
アジア太平洋の難病市場は、2023年から2030年にかけて重要な発展を遂げると考えられています。これは、アジア太平洋での脂肪性無色症を治療するための薬のための投機、臨床予備試験、組織の研究開発の上昇のためです。
その他の地域は、中東、アフリカ、ラテンアメリカに分けられます。先に述べた地域のダーカム病市場は、おそらく組織によるこの地域への資産と関心の高まりから発展が見られるでしょう。

主要企業
ダーカム病市場の主要企業にはPfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland)などが含まれます。

1.　エグゼクティブサマリー
2.　イントロダクション
3.　調査方法
4.　市場動向
5.　市場要因分析
6.　世界のダーカム病市場規模：治療法別
7.　世界のダーカム病市場規模：エンドユーザー別
8.　世界のダーカム病市場規模：流通チャネル別
9.　世界のダーカム病市場規模：地域別
10.　競争状況
11.　企業情報
12.　付録

❖ レポートの目次 ❖

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.4 FORECASTING TECHNIQUES

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.5.1 BOTTOM-UP APPROACH

3.5.2 TOP-DOWN APPROACH

3.6 DATA TRIANGULATION

3.7 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING PREVALENCE OF RARE DISEASES

4.2.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS AMONG THE PEOPLE ABOUT THE DISEASE

4.4 OPPORTUNITIES

4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 SALES AND DISTRIBUTION

5.1.4 POST-SALES REVIEW

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL DERCUM’S DISEASE MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON DEMAND

5.3.3 IMPACT ON MARKET

6 GLOBAL DERCUM’S DISEASE MARKET, BY TREATMENT

6.1 OVERVIEW

6.2 SURGERY

6.3 MEDICATION

6.3.1 DIURETICS

6.3.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUG

6.3.3 CORTICOSTEROIDS

6.3.4 OTHERS

6.4 LIPOSUCTION

6.5 ELECTROTHERAPY

6.6 ACUPUNCTURE

6.7 OTHERS

7 GLOBAL DERCUM’S DISEASE MARKET, BY END-USER

7.1 OVERVIEW

7.2 HOSPITAL & CLINICS

7.3 AMBULATORY SURGICAL CENTERS

7.4 OTHERS

8 GLOBAL DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL

8.1 OVERVIEW

8.2 HOSPITAL PHARMACIES

8.3 RETAIL PHARMACIES

8.4 OTHERS

9 GLOBAL DERCUM’S DISEASE MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.2 INDIA

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 FINANCIAL MATRIX

10.3.1 SALES (USD MILLION), 2022

10.3.2 R&D EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

11.1 PFIZER INC

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 ABBVIE, INC

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 KEY STRATEGIES

11.3 JOHNSON & JOHNSON SERVICES, INC

11.3.1 COMPANY OVERVIEWS

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 GLAXOSMITHKLINE PLC

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 BAUSCH & LOMB INCORPORATED

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTSS

11.5.5 KEY STRATEGIES

11.6 CALIWAY

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS/SERVICES OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGIES

11.7 RAZIEL THERAPEUTICS LTD

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 NIVARTA, INC.

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 BHR PHARMACEUTICALS LTD

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY STRATEGIES

11.10 NOVARTIS INTERNATIONAL AG

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 SWOT ANALYSIS

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL: DERCUM’S DISEASE MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL: DERCUM’S DISEASE MARKET, FOR MEDICATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL: DERCUM’S DISEASE MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL: DERCUM’S DISEASE MARKET, FOR DIURETICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL: DERCUM’S DISEASE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL: DERCUM’S DISEASE MARKET, FOR CORTICOSTEROIDS, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL: DERCUM’S DISEASE MARKET, FOR LIPOSUCTION, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL: DERCUM’S DISEASE MARKET, FOR ELECTROTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL: DERCUM’S DISEASE MARKET, FOR ACUPUNCTURE, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL: DERCUM’S DISEASE MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL: DERCUM’S DISEASE MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL: DERCUM’S DISEASE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL: DERCUM’S DISEASE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 22 GLOBAL: DERCUM’S DISEASE MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 28 US: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 29 US: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 30 US: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 31 US: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 32 CANADA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 33 CANADA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 34 CANADA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 35 CANADA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 36 EUROPE: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 37 EUROPE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 38 EUROPE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 39 EUROPE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 41 GERMANY: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 42 GERMANY: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 43 GERMANY: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 44 GERMANY: DERCUM’S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2018–2030 (USD MILLION)

TABLE 45 UK: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 UK: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 47 UK: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 48 UK: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 49 FRANCE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 50 FRANCE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 51 FRANCE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 52 FRANCE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 53 ITALY: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 54 ITALY: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 55 ITALY: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 56 ITALY: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 57 SPAIN: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 58 SPAIN: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 59 SPAIN: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 60 SPAIN: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 61 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 63 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 64 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 65 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 66 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 67 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 68 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 69 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 70 CHINA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 71 CHINA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 72 CHINA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 73 CHINA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 74 INDIA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 75 INDIA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 76 INDIA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 77 CHINA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 78 JAPAN: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 79 JAPAN: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 80 JAPAN: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 81 JAPAN: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 82 AUSTRALIA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 83 AUSTRALIA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 84 AUSTRALIA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 85 AUSTRALIA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 86 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 87 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 88 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 89 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 90 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 91 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 92 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 93 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 94 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY REGION, 2018–2030(USD MILLION)

TABLE 95 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 96 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 97 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 98 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 99 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 100 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 101 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 102 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 103 AFRICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 104 AFRICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 105 AFRICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 106 AFRICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 107 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 108 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 109 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 110 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 111 MAJOR PLAYERS IN THE GLOBAL DERCUM’S DISEASE MARKET

TABLE 112 PFIZER INC: PRODUCTS OFFERED

TABLE 113 ABBVIE, INC: PRODUCTS OFFERED

TABLE 114 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED

TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED

TABLE 116 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED

TABLE 117 3M: PRODUCTS/SERVICES OFFERED

TABLE 118 RAZIEL THERAPEUTICS LTD: PRODUCTS OFFERED

TABLE 119 NIVARTA, INC: PRODUCTS OFFERED

TABLE 120 BHR PHARMACEUTICALS LTD: PRODUCTS OFFERED

TABLE 121 NOVARTIS INTERNATIONAL AG: PRODUCTS OFFERED

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ダーカム病の世界市場（〜2030）(Global Dercum’s Disease Market Research Report Forecast till 2030)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

ダーカム病の世界市場（〜2030）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp